Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system
The clearance expands the system's capabilities for neuromuscular monitoring, strengthening competitive advantages.
See the latest news and media coverage for Senzime. We track all announcements, press releases, and industry mentions in real time, all in one place.
Precision-based patient monitoring solutions provider
senzime.comLast updated
In short: Senzime achieved significant U.S. market expansion, secured FDA clearance for its enhanced TetraGraph system, and reported record annual sales.
The clearance expands the system's capabilities for neuromuscular monitoring, strengthening competitive advantages.
The TetraGraph System is included in Vizient, Premier, and HealthTrust agreements, improving procurement access and shortening potential sales cycles.
The report highlights sales exceeding SEK 100 million, goal achievement, strategic wins, and profitability foundation for 2026. CEO Philip Siberg comments on growth.
Net sales dipped 1% to SEK 23.2M due to US delays, but full-year targets remain on track with profitability by year-end.
Senzime AB ( (SE:SEZI) ) has shared an announcement.
UPPSALA, SE / ACCESS Newswire / May 27, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that its TetraGraph® neuromuscular monitoring system has received...
UPPSALA, SE / ACCESS Newswire / May 19, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - The annual general meeting in Senzime AB ...
UPPSALA, SE / ACCESS Newswire / April 24, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that the TetraGraph System has secured inclusion in...
Track Senzime and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Senzime and other trending companies.